ClinicalTrials.gg
DrugRead study by study

AZD9833 clinical trials

Also written AZD9833 and Camizestrant.

studies test it
20
open now
7
in phase 3
7
first study started
2018
ClinicalTrials.gov finds 17 studies for AZD9833. How that becomes 20 here

Every study that search finds has been read, to see whether and how it gives AZD9833. ClinicalTrials.gov counts as of Nov 17, 2026. How drug pages count

  1. 17Found by its intervention search · See all 17 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 12 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. +5Give it under a name that search misses: a biosimilar’s code or a misspelling
  3. 22Give AZD9833 to participants
  4. −2Give it beside what is tested
  5. 20Test it: the count on this site

Get an email when these change. Save the AZD9833 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
4 Sept 2026 · ETCAMAH · NDA 220359 (FDA, Drugs@FDA)
European Union
20 Jul 2026 · Etcamah · EMEA/H/C/006494 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

AZD9833
14

Other names

Camizestrant
10

In one entry with another drug

Given together, or one or the other

AZD9833 with palbociclib
2
AZD9833 with everolimus
2

Studies by the year they started

20 studies that test it; most in 2026 (5)

Studies that test AZD9833, by start year
YearStudies
20181
20204
20213
20222
20233
20242
20265

By phase

A phase 1/2 study counts in both.

Phase 1
8
Phase 2
5
Phase 3
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 17 · Other 3

AstraZeneca (17) · University Health Network, Toronto (1) · UNICANCER (1) · MedSIR (1)

Often tested with

Tested in the same studies.

Celecoxib (1) · AZD5305 (1) · Letrozole (1) · Atirmociclib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 2 most studied

New when their studies opened, with AZD9833 beside them; studies of each.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test AZD9833, phase 3 first.

Studies

Open first, then newest update. How each study uses AZD9833 has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 20

Behind its US label · 1 — the studies the FDA label of ETCAMAH describes

From the Clinical Studies section of ETCAMAH (2026-09), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 7 — no other medicine in its arm
Tested with established drugs · 10 — they are given beside it
Tested in a combination · 3 — another drug in the study is under test too
Beside a new treatment under test · 2 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with AZD9833: Gatsuciclib 1 · AZD5305 1

Codes

What other systems call AZD9833 · ClinicalTrials.gg INT001822

  • MeSH (NLM) C000722187AZD9833One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion